Anti-Human **ULBP2 Monoclonal Antibody** BUMO1

Antigen: **Human ULBP2 (UL16-binding protein 2)**



Human cell line 293T stained with BUMO1 (black) or IgG1 isotype (dotted) and goat anti-mouse Ig-PE conjugate.

Clone: BUMO1, mouse IgG1

Catalog Number: BUMO1-100

Specificity: binds: ULBP2
binds not: ULBP1,ULBP3,ULBP4

Epitope: in ULBP2 ectodomain

Applications: Flow cytometry

Size: 100 µg, 1.0 mg/ml, in 0.1 ml phosphate-buffered saline, pH 7.4 with 0.05% sodium azide (**Caution**: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing).

Usage: In general, for flow cytometry we recommend a final dilution of 10µg mAb/ml and for ELISA 1-10 µg mAb/ml.

Purification: Protein A affinity chromatography

Storage: Store at 4°C. For long-term storage freezing at -80°C is recommended.

Description: UL16-binding proteins (ULBP) have been discovered in 2001 during a search for human proteins binding the Human Cytomegalovirus-encoded UL16 glycoprotein [1] and for human homologues of the mouse RAE1 ligands of NKG2D, respectively [2]. ULBP1-4 are cell surface proteins with an MHC class I-like $\alpha 1/\alpha 2$ superdomain that is bound by human NKG2D [1-3]. ULBP1-3 are attached to the cell surface by GPI-anchor [1]. Expression of ULBP is induced by infection with Human Cytomegalovirus (HCMV) [4]. In vivo expression of ULBP2 is mostly unexplored, except that freshly isolated leukemias have been shown to express ULBP2 [5]. ULBP2 is released from tumor cells by metalloproteases in a manner similar to MIC molecules and can be found in sera of some leukaemia patients [6]. Like other human and mouse NKG2D-ligands, ULBP stimulate tumor immunity in vivo [7].

Conditions: **For research use only. Not for use in diagnostic or therapeutic procedures. BAMOMAB is not responsible for any patent infringements caused by the use of this product.**

Country of Origin: Germany

Literature:

1. Cosman et al. *Immunity* **14**,123-133 (2001).
2. Steinle A et al. *Immunogenetics* **53**, 279-287 (2001).
3. Radaev S et al. *Immunity* **15**,1039-1049 (2001).
4. Welte S et al. *Eur J Immunol* **33**, 194-203 (2003).
5. Salih HR et al. *Blood* **102,** 1389-1396 (2003).
6. Waldhauer I et Steinle A. *Cancer Res* **66**, 2520-2526 (2006).
7. Sutherland C et al. *Blood* **108**:1313-1319 (2006).

BAMOMAB GmbH, Ruffiniallee 15a, 82166 Gräfelfing, Germany.
Fax ++49-(0)89-3303-7335 www.bamomab.com order@bamomab.com